A comparative study of a new tumour marker, CA242, and CA19-9 was conducted with special reference to their diagnostic usefulness in pancreatic cancer. CA242 showed senstivity similar to that of the C241 catcher antibody of this assay system, which has alnost the same epitope specitity as the C50 and the NS19-9 monoclonal antibodies. In conusio, CA242 is superior to CA19-9 in diagning pancreatic cancer by virtue of its higher specificity.
The therapeutic results and prognosis of adenocarcinoma of the exocrine pancreas are poor, because almost all patients are already in an advanced stage at diagnosis. Methods for early detection are urgently needed to improve this situation. For this purpose, mass screening studies on asympomatic individuals or outpatients on their first visit have been carried out using the serum assay of CAl9-9, which has been widely used as a tumour marker for the diagnosis of pancreatic cancer (Koprowski et al., 1979; Frebourg et al., 1988; Homma & Tsuchiya, 1991) . Although the efficiencies of these studies were controversial, outpatient screening was revealed to be useful in detecting some curable cases of pancreatic cancer (Homma & Tsuchiya, 1991) . However, false-positive elevation of serum CAl9-9 has been noted, especlly in benign hepatobiiary disases and chronic pancreatitis, which are so tmes difficult to differentiate from pancreatic cancer at the time of admission (Frebourg et al., 1988) . The false positivity leads to further examinations, such as computerised tomography (CT) or endoscopec retrograde cholangiopancreatography (ERCP), which are wasteful of these facilities. To improve the effectiveness of the screening tests for pancreatic cancer, it is necessary to use more cancer-specific tumour markers without reducing the sensitivity attained by CA242 is a cancer-associated glycoconjugate expressed in mucin and found predominantly in the sera of pancreatic cancer patients . The struture of CA242 has not been fullly elucidated, but it is different from other established cancer-associated glycoconjugates, such as sialosyl-fucosyl-lactotetraose or sialosyl lactotetraose (Johanson et al., 1991a; Kuusela et al., 1991) . A sensitive serum assay system using ime-resolved fluoroimmunoassay (TRFIA) was developed, and favourable clinical results were reported for the diagosis of pancreatic cancer, colorectal cancer and other digestve tract malignancies (Kuusela et al., 1991; Nilsson et al., 1992; Pasanen et al., 1992) . With respect to the diagnosis of pancreatic cancer, CA242 has been demonstrated to have sensitivity close to or slightly lower than that of CAl9-9 but it is more specific (Nilsson et al., 1992; Pasanen et al., 1992; Banfi et al., 1993; Rothlin et al., 1993 level is less frequently elevated. In addition, like CA19-9, it is elevated in the sera of half of the patients with resectable pancreatic cancer (Kuusela et al., 1991 Turku, Finland) , in which C241 and C242 monoclonal antibodies were used as catcher and tracer antibodies respectively, according to the manufacturer's instructions. In this study, the cut-off level of CA242 was established from the results of normal subjects and by the receiver operating characteristic (ROC) curve from the results of the patients with pancreatic cancer and benign dieases including chronic pancreatitis, chronic hepatitis and liver cirrhosis. Serum CA19-9 levels were measured by a radioinmunoassay kit (Centcor, PA, USA), applying the recommended cut-off level of 37 U ml-1, which was established from results in normal subjects (Del Villano et at., 1983) and is widely used in Japan. Clinical results of both markers were also compared at 90% specificity for the differentiation between pancreatic cancer and benign diseases.
Statistical analysis
The differences among each Lewis phenotype group in normal subjects were evaluated by analysis of variance (ANOVA). A value of P<0.05 was regarded as statistically significant.
Reslts
ROC analysis Tlhe ROC analysis showed that the CA242 test was more sensitive than the CAl9-9 test at specificity levels of 75-95%
( Figure 1 ).
Sensitivities in various diseases
In this study, the cut-off level of CA242 was defined as 30 U ml-', calculated from the mean + 3 s.d. of serum kvels in the normal subjects. As shown by the ROC curve ( Figure  1 ), this vahle gives the best discrimination betwen pancreatic cancer and benign diseases. In addition, cut-off klevls corresponding to a 90% specificity were also caklulated from the ROC curves as 26 and 47Uml-' for CA242 and CAI9-9 respectively. Figure 2a summarises the sensitivities in various conditions at the cut-off levels obtained from normal subjects (CA242, 30 U ml-'; CA19-9, 37 U ml-'). The sensitivity of CA242 in 151 pancreatic cancer patients was high (79%) and similar to that of CA19-9 (82%). In other malignant diseases, the sensitivity of CAl9-9 was higher than that of CA242 except for colorectal cancer. In addition, a significant difference in sensitivity between the two markers was observed in patients with hepatoma, the positive rate for CA242 being 7% and that for CAl9-9 35%. In benign diseases, serum CA242 levels were less frequently elevated than those of CA19-9. There were marked differences in the positive rates and actual values of the two markers in patients with benign obstructive jaundice (Figure 3 ), indicating that CA242 is only slightly affected by cholstasis. This weak effect of cholstasis on the sern elevation may account for the lower positive rates of this marker in benign hepatic diseases and hepatoma compared with CA19-9. The sensitivities of the two markers were also compared using cut-off levels corresponding to a 90% specificity (Figure 2b) . The sensitivity of CA242 in pancreatic cancer (81%) was again similar to that of CAl9-9 (79%). that of CA19-9. In benign obstructive jaundice, the sensitivity of CA242 was significantly lower than that of CAl9-9.
Comparison of CA242 and CA 19-9 in benign pancreatic and liver diseases The actual values of the two markers were compared in patients with chronic pancreatitis and benign liver dises, in whom the level of the two markers exceeded the cut-off levels obtained from normal subjects (Figure 4 ). In such benign conditions, the positivity of CA242 was not as high as that of CAl9-9, and the level scarcely exceeded 100 U ml, although the cut-off levels were similar.
Correlation between positive ratio and TMN staging of the pancreatic cancer
To confirm the diagnostic efficiency of the two markers for early-stage pancreatic cancer, the results obtained by TMN staging (UICC) were compared using various cut-off levels (Table II) . For stage I tumours, including almost all patients undergoing curative operation, the positivity of CA242 (41%) was similar to that of CAl9-9 (47%) using the cut-off levels obtained from normal subjects. However, CAl9-9 was falsely negative in some patients with stage I tumours using cut-off levels corresponding to 90% specificity against various benign conditions. These results indicated that for CA19-9 it was preferable to use the cut-off level obtained from normal subjects for the detection of early-stage pancreatic cancer, and the comparison of diagnostic utility should be done at this cut-off level.
Comparison ofsensitivity and specificity in diagnosing pancreatic cancer
The sensitivity and speificity of the two markers in the diagnosis of pancreatic cancer were compared using cut-off levels obtained from normal subjects (Table III) . Although the sensitivities of the two markers were imilar, the specificity of CA242 was higher than that of CAI9-9 calculated from the results of chronic pancreatitis, benign liver diseases and both conditions combined.
Correlation between serun levels of the two markers As shown in Figure 5, Influence of Lewis blood group system on sernm levels in normal subjects
As shown in Figure 6 , the serum CA242 levels in normal subjects were influenced by the Lewis blood group system, as was the serum CA19-9 level. Among the three phenotypes, a significantly lower level was found in Le(a-b-) and Le(a-b+) groups than in the Le(a+b-) group.
Mcsson
In this study, we confirmed that CA242 is a more useful marker than CA19-9 for detecting curable cases of pancreatic cancer among outpatients on their first visit, because of the similar sensitivities for overall cases and cases of early-stage (stage I) pancreatic cancer, and the higher specificity resulting from the less frequent and lower elevation in benign diseases. These results were similar to previous reports (Kuusela et al., 1991; Nilsson et al., 1992; Pasanen et al., 1992) and superior to other studies (Banfi et al., 1993; Rothlin et al., 1993) . Although (Schmigel et al., 1985; Tatsuta et al., 1985; Malesci et al., 1987; Kawa et al., 1990) and liver diseases (Jalanko et al., 1984; Steinberg et al., 1986; Kawa et al., 1990; Kobayashi et al., 1991) and false-negative results in cancer patients with Lewis-negative phenotype (Hirano et al.. 1987; Margaret et al., 1987; Kawa et al., 1991) .
The clinical usefulness of CAI9-9 in this study was similar to that reported previously, supporting the validity of the present study. The sensitivity of CA242 for pancreatic cancer was similar to that of CAI 9-9, and CA242 has been reported to be expressed on pancreatic cancer tissues to a similar extent as CA19-9 (Haglund et al., 1989) . However, no relationship was observed between the serum levels of the two markers in this study. As suggested previously (Johanson et al., 1991a -, Kuusela et al., 1991 , the two structures may be different. The overall sensitivity of CA242 in other malignant diseases is lower than that of CA19-9. However, for other malignancies, more useful diagnostic tools than tumour markers can be used. Therefore, these disadvantages are negligible in the clinical use of this marker. On the other hand, CA242 gave better results in colorectal cancer than CA19-9, which is in agreement with previous findings (Kuusela et al., 1991; Nilsson et al., 1992) . Its usefulness was more apparent at cut-off levels corresponding to 90% specificity. Moreover, CA242 has been reported to be useful in the diagnosis of early-stage colorectal cancer (Dukes' A and B) and a valuable complement to CEA (Kuusela et al., 1991; Nilsson et al., 1992) . In hepatoma, a significant difference in the positive rate was noted between the two markers. CA19-9 is expressed not on hepatoma cells but on bile duct cells. The mechanism of serum elevation of CA19-9 is considered to be cholestasis or damage to the bile duct cells (Kobayashi et al., 1991) . Although the exact mechanism of this elevation has not been elucidated, CA242 may be only slightly affected by these abnormal conditions, which was further demonstrated by the results obtained in the patients with benign obstructive jaundice.
We have confirmed that CA242 is as useful as CA19-9 in the diagnosis of stage I pancreatic cancer, including curative resectable disease, using the cut-off level obtained from normal subjects. By using cut-off levels corresponding to 90% specificity for various benign conditions, CA19-9 was falsely negative in some patients with stage I tumour, although the sensitivities of the two markers overall were similar. Resectability is considered to be an important predictor of the prognosis (Saito, 1990) , and CA19-9 has been reported to be useful in the diagnosis of 50-79% of patients with resectable pancreatic cancer (Sakahara et al., 1986 , Kawa et al., 1990 Kobayashi et al., 1991) . As with CA19-9, CA242 has also been reported to be positive in half of patients with resec- (Kuusela et al., 1991) . However, it may be clinically impractical to search for early pancreatic cancer such as stage I tumours more extensively using a tumour marker alone, and it is necessary to develop a screening system combined with other methods, such as ultrasonography, to improve the usefulness of the early diagnosis. The major advantage of CA242 over CAl9-9 is its higher specificity resulting from the less frequent and only slight elevation in the serum level in patients with chronic pancreatitis, benign liver diseases and benign obstructive jaundice, which was confirmed by the present study and previous reports (Johansson et al., 1991b; Kuusela et al., 1991; Nilsson et al., 1992; Pasanen et al., 1992) . The differential diagnosis of pancreatic cancer from chronic pancreatitis is sometimes difficult. In patients with liver diseases, false-positive elevation of CA 19-9 is frequently on the first visit to the clinic (Frebourg et al., 1988) . Accordingly, the good discrimination provided by CA242 will avoid unnecessary further examination of the patient. CAI 9-9 has been demonstrated to be expressed on the duct cells of the pancreas and bile duct cells of the liver (Arends et al., 1983; Kobayashi et al., 1991) and secreted in the pancreatic juice and bile in both healthy subjects and patients with pathological conditions (Schmiegel et al., 1985) . In benign diseases, the antigen is considered to be released into the circulation by stagnation of pancreatic juice, cholestasis or damage to the pancreatic and bile duct. However, tissue expression of CA242 in the normal pancreas and in chronic pancreatitis is reported to be similar to that of CA19-9 (Haglund et al., 1989) . Therefore, it is uncertain why CA242 is less influenced by these conditions. A notable characteristic of CA242 is that its serum level is scarcely affected by cholestasis, which was demonstrated by less frequent and slight elevation in sera of patients with benign obstructive jaundice. The clinical results obtained in benign liver diseases may also be associated with this characteristic. Further studies, including immunohistochemistry, are necessary to clarify the exact mechanism.
In this study, the CA242 assay system was shown to be influenced by the Lewis blood group system, as in the CA19-9 assay. This drawback is considered to be attributable to the C241 catcher antibody of the assay system, because the C241 monoclonal antibody has almost the same epitope specificity as the NSl9-9 monoclonal antibodies used in the CA50 and CA19-9 assay systems, whereas the C50 antibody also recognises sialylated lact-N-tetraose to a small degree Johansson et al., 1991a) . In a previous study, we confirmed that the plasma expression of CA50 is similar to that of CAl9-9 with respect to Lewis blood cell status (Kawa et al., 1991) . We also found that Lewis-negative patients constituted one-third of the CA19-9-negative patients, and the Dupan-2 assay provides a complementary method for these patients (Kawa et al., 1991) . Accordingly, for CA242-negative patients who are suspected to have pancreatic cancer, an additional Dupan-2 assay is recommended.
In conclusion, CA242 is superior to CA19-9 in the diagnosis of pancreatic cancer because of its higher specificity, and it may be useful in the screening of localised or resectable tumours.
